Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s
Webinar

Keynote webinar | Spotlight on advances in lupus

LIVE: Tuesday 27th May 2025, 18:00-19:15 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in:

07-12-2024 | Neuroendocrine Tumor | ASO Author Reflections

ASO Author Reflections: The Utility of PRRT upon Progression After Resection and Cytoreduction of GEP-NETs

Authors: James R. Howe, MD, Scott K. Sherman, MD, Joseph S. Dillon, MB, BCh

Published in: Annals of Surgical Oncology | Issue 2/2025

Login to get access

Excerpt

As the incidence of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) continues to rise, surgical oncologists are becoming more and more familiar with the complexities of managing these patients. Many will present with metastatic disease, predominantly in the liver, but also in bone and retroperitoneal and extra-abdominal lymph nodes. The most important initial therapeutic step in most patients is a good operation, with removal of the primary tumor and regional lymph nodes. Metastatic disease to the liver is often the biggest threat to longevity, so cytoreduction of these lesions is also an important consideration for management. …
Literature
1.
Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46(6):715–31.CrossRefPubMedPubMedCentral
2.
Singh S, Halperin D, Myrehaug S, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807–17.CrossRefPubMed
3.
Strosberg J, Kunz PL, Hendifar A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47(10):2372–82.CrossRefPubMedPubMedCentral
4.
Tobias J, Abou Azar S, Gujarathi R, et al. Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2024 (in press).
5.
Metadata
Title
ASO Author Reflections: The Utility of PRRT upon Progression After Resection and Cytoreduction of GEP-NETs
Authors
James R. Howe, MD
Scott K. Sherman, MD
Joseph S. Dillon, MB, BCh
Publication date
07-12-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2025
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-16666-y

Other articles of this Issue 2/2025

Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy

ASO Visual Abstract: Impact of Surgeon-Radiation Oncology Dyads in Oral Cavity Cancer Outcomes

  • ASO Visual Abstract

ASO Author Reflections: The Present and Future of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE)

ASO Visual Abstract: Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors

  • ASO Visual Abstract

ASO Visual Abstract: Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

  • ASO Visual Abstract

ASO Visual Abstract: Clinical Outcomes for Early-Stage Node-Negative HER2-Positive Breast Cancer Patients Receiving Upfront Surgery or Neoadjuvant Systemic Therapy

  • ASO Visual Abstract
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now
Video
Image Credits